Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
about
A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerMolecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case PresentationTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentAnnual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based studyOpportunities for improving triple‐negative breast cancer outcomes: results of a population‐based studyUS incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerEfficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trialsRegular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.Computational analysis of mRNA expression profiles identifies the ITG family and PIK3R3 as crucial genes for regulating triple negative breast cancer cell migrationThe prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based studyA BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.Correlation Factors Analysis of Breast Cancer Tumor Volume Doubling Time Measured by 3D-UltrasoundMolecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERKLeptomeningeal metastases in breast cancer.Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.Expanded Indications and Improved Outcomes for Nipple-Sparing Mastectomy Over Time.Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment FactorsSelective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.Racial differences in outcomes of triple-negative breast cancerLipid analysis of eight human breast cancer cell lines with ToF-SIMS.Prognostic effect analysis of molecular subtype on young breast cancer patientsHealth disparities across the breast cancer continuumTriple negative breast cancer in North of Morocco: clinicopathologic and prognostic featuresA TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.Breast carcinoma subtypes show different patterns of metastatic behavior.Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.Decreased Wnt5a Expression is a Poor Prognostic Factor in Triple-Negative Breast Cancer.Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanismBreast cancer brain metastases: new directions in systemic therapyPrognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patientsFeatures of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer databaseDeriving clinically meaningful cut-scores for fatigue in a cohort of breast cancer survivors: a Health, Eating, Activity, and Lifestyle (HEAL) Study.The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.
P2860
Q26752846-8D812A35-0555-400C-8D01-CAD7A7B7D3FCQ26800626-FF53616E-4905-4610-875C-3DE94F7C03A9Q27009424-610BE0DF-405C-476D-B1A5-5F6F3A47DE4FQ27300459-6FD53700-1DE3-424E-A1BB-8A5288895149Q29248323-F897FBC4-5050-418F-9FC5-62351795B62EQ29248325-548E9A79-AC0C-4A8B-850A-BE8F29B1C8D9Q30665329-A6201C7D-DEDF-4CDE-A96D-2106FB18C89FQ33414349-83CEBB29-8E1F-448A-9351-FAB735DB75A9Q33438050-59E83052-E6D8-4A64-B6FB-4161C05DDE8EQ33619700-EB655F94-B1C5-4CEB-B138-24572A3B1F14Q33657062-45A323CF-264D-4E38-872D-C9500C373AEEQ33688668-375E594E-E1E7-4E17-A9C2-CF4C75334516Q33739161-3ACC386F-7ACB-48E6-AAC0-78EB32B6726DQ33874429-0EBC71C9-D368-46E6-AE9F-3071769223A3Q34196915-EE18BD2D-4A78-40FE-9F17-A6A59EFF2F2AQ34296476-276064A3-8E99-436B-82FE-D027210FBAFAQ34309459-ED70E1E6-2EFC-467F-AF62-5D50D8D1C3D3Q34571374-9F260067-5543-4AC4-8AE6-25C3547FF08DQ34650605-49FB25E1-DF20-4609-B4B8-EB403D17821AQ35088745-AA7DB075-8A2B-4A02-8737-D7E2D723B2C6Q35707085-66176BA2-27D6-4A5C-8E24-E1F3D4D2F990Q35801283-23086F98-C601-48CB-98DE-41AC88EC688FQ35921549-42C3F81F-38B5-4398-B0B7-D9CF066DFA1BQ35956986-6663197B-093F-4C6F-AD32-663F9D555844Q36004758-7A820EEA-ED40-4C47-908D-2D1228863C4FQ36029962-83DA2536-3EA1-4EDD-AF9D-36C2B6844932Q36136670-B60EB174-9569-43DF-915E-5CD704EC0D54Q36172054-EB252ABB-BDE8-4AE0-9703-6A8B63B7E92CQ36244860-1C500969-5F64-4993-B1BC-46E58A99320EQ36253544-023EF2B7-74EE-4092-9C33-B733070325DCQ36373733-6CB0154E-4030-43CC-9653-D77FCA19B5AAQ36429159-1DE59214-4435-4BF9-A7F8-5D56C69CFB5DQ36467458-00D442FF-3FF4-4FB3-8F16-FDF19D04D644Q36651026-92C77E68-A2B4-475B-A598-1B1123021631Q36734590-8A477558-B143-46AF-A28F-B24C18D9AF09Q36822500-2E1BD83B-A69E-4B2A-9C2C-1B51793AC8FAQ36874902-C82595F5-F467-4032-9103-591CECF0C0D4Q37226242-5B391C14-9B62-4F33-AA5A-5D17F68AA4FBQ37296936-E3D16A00-B062-4943-8382-50A0DE32E543Q37304764-B965849E-92D2-4752-BF66-70A1C5C54DC9
P2860
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@ast
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@en
type
label
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@ast
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@en
prefLabel
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@ast
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@en
P2093
P2860
P356
P1433
P1476
Clinicopathologic features, pa ...... l Comprehensive Cancer Network
@en
P2093
Ann Vanderplas
Douglas W Blayney
Eric P Winer
Jane C Weeks
Joyce C Niland
Melissa E Hughes
Nancy U Lin
Richard L Theriault
Stephen B Edge
Yu-Ning Wong
P2860
P304
P356
10.1002/CNCR.27581
P407
P577
2012-04-27T00:00:00Z